H.C. Wainwright analyst Arthur He downgraded BioAtla (BCAB) to Neutral from Buy without a price target The firm is awaiting clarity on the company’s pipeline development path. The firm says that with pipeline decisions pending, it is unable to project the cadence of BioAtla’s revenue at this time.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter